Emanuele Carosati

Dr. Emanuele Carosati


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2024 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
FLFengling Li
Fengling Li
SASuzanne Ackloo
Suzanne Ackloo
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith
FBFuqiang Ban
Fuqiang Ban
CBChristopher J. Barden
Christopher J. Barden
MSMatthieu Schapira
Matthieu Schapira

11 April 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ECEmanuele Carosati
Emanuele Carosati
RMRaimund Mannhold
Raimund Mannhold
PWPhilip Wahl
Philip Wahl
JHJohn Bondo Hansen
John Bondo Hansen
TFTinna Fremming
Tinna Fremming
MBMassimo Baroni
Massimo Baroni

25 July 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Maura MarinozziMaura Marinozzi
Maura Marinozzi
FNFrancisco Fermin Castro Navas
Francisco Fermin Castro Navas
DMDaniela Maggioni
Daniela Maggioni
ECEmanuele Carosati
Emanuele Carosati
GBGiovanni Bocci
Giovanni Bocci
VRVincenzo Russo
Vincenzo Russo
A series of stigmasterol and ergosterol derivatives, characterized by the presence of oxygenated functions at C-22 and/or C-23 positions, were designed as potential liver X receptor (LXR) agonists. The absolute configuration of the newly created chiral centers was definitively assigned for all the corresponding compounds. Among the 16 synthesized compounds, 21, 27, and 28 were found to be selective LXRα agonists, whereas 20, 22, and 25 showed good selectivity for the LXRβ isoform. In particular, 25 showed the same degree of potency as 22R-HC (3) at LXRβ, while it was virtually inactive at LXRα (EC50 = 14.51 μM). Interestingly, 13, 19, 20, and 25 showed to be LXR target gene-selective modulators, by strongly inducing the expression of ABCA1, while poorly or not activating the lipogenic genes SREBP1 and SCD1 or FASN, respectively.

13 July 2012 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
FBFabio Broccatelli
Fabio Broccatelli
RMRaimund Mannhold
Raimund Mannhold
AMAlessio Moriconi
Alessio Moriconi
SGSandra Giuli
Sandra Giuli
ECEmanuele Carosati
Emanuele Carosati

5 November 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ECEmanuele Carosati
Emanuele Carosati
ATAnna Tochowicz
Anna Tochowicz
GMGaetano Marverti
Gaetano Marverti
GGGiambattista Guaitoli
Giambattista Guaitoli
PBPaolo Benedetti
Paolo Benedetti
MCMaria Paola Costi
Maria Paola Costi

1 February 2007 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Roberta BudriesiRoberta Budriesi
Roberta Budriesi
BCBarbara Cosimelli
Barbara Cosimelli
PIPierfranco Ioan
Pierfranco Ioan
ECEmanuele Carosati
Emanuele Carosati
MUMaria P. Ugenti
Maria P. Ugenti
RSRraffaella Spisani
Rraffaella Spisani
Cardiovascular diseases as hypertension, angina and/or supraventricular arrhythmias are among the most important death causes in the world. For the treatment of heart pathologies, calcium channel entry blockers are very important drugs, owing to their therapeutic versatility. Although few calcium antagonists described until today are structurally related to diltiazem and to the benzothiazepine class, the still high pharmaceutical interest on diltiazem analogues justifies this review. Diltiazem and its first analogues developed in the early 70s became popular in the 80s, and were pharmacologically characterized for a long time. It is in the 90s that several research groups carried out structural variations identifying novel scaffolds for diltiazem-related compounds, with significant calcium antagonist behaviour. Recently, a series of thiazino-oxadiazolone derivatives were identified as potent and selective antagonists for calcium influx into cardiac cells, and they were subsequently used to search for novel chemotypes by means of virtual screening techniques. The resulting hits could open interesting perspectives for the development of drugs to treat cardiovascular diseases. In the present review, an updated collection of diltiazem analogues is reported over the last ten years. The chemical structure and the structure activity relationships will be given, with additional mention to the potential therapeutic applications.